NASDAQ:MYL - Mylan Stock Price, Price Target & More

$40.72 -0.09 (-0.22 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$40.72

Today's Range$40.43 - $40.99

52-Week Range$29.39 - $47.82

Volume3.39 million shs

Average Volume5.06 million shs

Market Capitalization$20.97 billion

P/E Ratio8.93

Dividend YieldN/A

Beta1.34

About Mylan (NASDAQ:MYL)

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:MYL

CUSIP62853010

Webwww.mylan.com

Phone44-0-17-0785-3000

Debt

Debt-to-Equity Ratio1.06%

Current Ratio1.13%

Quick Ratio0.73%

Price-To-Earnings

Trailing P/E Ratio8.93

Forward P/E Ratio7.60

P/E Growth1.32

Sales & Book Value

Annual Sales$11.91 billion

Price / Sales1.76

Cash Flow$7.9222 per share

Price / Cash5.14

Book Value$24.81 per share

Price / Book1.64

Profitability

EPS (Most Recent Fiscal Year)$4.56

Net Income$696 million

Net Margins5.84%

Return on Equity19.14%

Return on Assets6.92%

Miscellaneous

Employees35,000

Outstanding Shares514,780,000

How to Become a New Pot Stock Millionaire

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.02. The business had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.29 billion. Mylan had a return on equity of 19.14% and a net margin of 5.84%. The company's quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.57 earnings per share. View Mylan's Earnings History.

When is Mylan's next earnings date?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Mylan.

What guidance has Mylan issued on next quarter's earnings?

Mylan updated its FY18 earnings guidance on Wednesday, April, 11th. The company provided earnings per share (EPS) guidance of $5.20-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.38. The company issued revenue guidance of $11.75-13.25 billion, compared to the consensus revenue estimate of $12.43 billion.

What price target have analysts set for MYL?

19 brokerages have issued 12-month target prices for Mylan's shares. Their predictions range from $29.39 to $59.00. On average, they expect Mylan's share price to reach $47.2311 in the next twelve months. View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:

1. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) The North America segment was down 8%, excluding Epipen, which declined $131.9MM in 4Q17, and $655.4MM in 2017. EU grew 16% in the quarter, and Rest of World grew 12%. 2) Generic drug pricing continued to be a headwind in the U.S. during the quarter. However, favorable pricing on existing products in Europe was a tailwind in 4Q17. 3) The Restasis target action date is in July 2018. The Biosimilar pegfilgrastim target action date is in early June. 4) MYL repurchased 12.4MM shares during 2017, and an additional 9.8MM shares in January 2018. 4) MYL expects to launch generic Adavir and Neulasta in 2018, and has risk-weighted these launches in its 2018 guidance." (3/1/2018)
2. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018)
3. Argus analysts commented, "junior version" (8/22/2017)

Are investors shorting Mylan?

Mylan saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 17,578,475 shares, a drop of 14.1% from the March 15th total of 20,463,110 shares. Based on an average daily volume of 4,309,865 shares, the short-interest ratio is currently 4.1 days. Approximately 3.6% of the shares of the company are short sold.

Who are some of Mylan's key competitors?

Some companies that are related to Mylan include Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Nektar Therapeutics (NKTR), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Genmab As (GNMSF), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE) and SAGE Therapeutics (SAGE).

Has Mylan been receiving favorable news coverage?

Press coverage about MYL stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mylan earned a daily sentiment score of 0.09 on Accern's scale. They also gave media stories about the company an impact score of 44.46 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $40.72.

How big of a company is Mylan?

Mylan has a market capitalization of $20.97 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

How can I contact Mylan?

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]

MarketBeat Community Rating for Mylan (MYL)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		592 (Vote Outperform)
Underperform Votes:		426 (Vote Underperform)
Total Votes:		1,018

MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Mylan (NASDAQ:MYL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Mylan in the last 12 months. Their average twelve-month price target is $47.2311, suggesting that the stock has a possible upside of 15.99%. The high price target for MYL is $59.00 and the low price target for MYL is $29.39. There are currently 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.74	2.68	2.61	2.61
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$47.2311	$46.81	$44.2994	$40.9619
Price Target Upside:	15.99% upside	11.40% upside	5.30% downside	6.37% upside

Mylan (NASDAQ:MYL) Consensus Price Target History

Price Target History for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/12/2018	JPMorgan Chase	Set Price Target	Buy	$53.00	Low
4/12/2018	Leerink Swann	Upgrade	Market Perform -> Outperform	$44.00	Low
4/11/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Medium
4/9/2018	Morgan Stanley	Set Price Target	Buy	$50.00	High
4/3/2018	Royal Bank of Canada	Set Price Target	Hold	$45.00	Low
3/15/2018	Mizuho	Boost Price Target	Buy	$45.00 -> $51.00	Low
3/1/2018	UBS	Set Price Target	Buy	$54.00	High
1/25/2018	Susquehanna Bancshares	Reiterated Rating	Positive -> Positive	$47.00 -> $55.00	Low
1/24/2018	Deutsche Bank	Set Price Target	Buy	$50.00	Low
1/18/2018	Wells Fargo	Set Price Target	Hold	$33.00 -> $43.00	Low
1/11/2018	Goldman Sachs	Boost Price Target	Buy	$46.00 -> $52.00	High
1/4/2018	Citigroup	Reiterated Rating	Buy -> Buy	$48.00 -> $58.00	High
12/12/2017	Guggenheim	Initiated Coverage	Buy -> Buy	$59.00	Low
10/5/2017	Instinet	Reiterated Rating	Buy	$37.00	N/A
10/5/2017	Cowen	Reiterated Rating	Market Perform	$30.00 -> $36.00	N/A
10/4/2017	BTIG Research	Boost Price Target	Buy -> Buy	$42.00 -> $45.00	High
9/29/2017	BMO Capital Markets	Reiterated Rating	Buy	$45.00	Low
8/22/2017	Argus	Downgrade	Buy -> Hold	$47.59 -> $29.39	Low
5/22/2017	Barclays	Upgrade	Equal Weight -> Overweight	$47.00 -> $50.00	Low
12/30/2016	Stifel Nicolaus	Reiterated Rating	Positive		N/A
10/10/2016	Raymond James	Upgrade	Market Perform -> Strong-Buy	$57.00	N/A
9/23/2016	Sanford C. Bernstein	Set Price Target	Buy	$60.00	N/A
8/26/2016	Evercore ISI	Reiterated Rating	Hold	$49.00	N/A
8/24/2016	Bank of America	Reiterated Rating	Buy	$70.00	N/A

(Data available from 4/21/2016 forward)

Mylan (NASDAQ:MYL) Earnings History and Estimates Chart

Earnings by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Earnings Estimates

2018 EPS Consensus Estimate: $5.40

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.92	$0.92	$0.92
Q2 2018	1	$1.22	$1.22	$1.22
Q3 2018	1	$1.46	$1.46	$1.46
Q4 2018	1	$1.80	$1.80	$1.80

Mylan (NASDAQ MYL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018		$1.07					N/A
2/28/2018	Q4 2017	$1.41	$1.43	$3.2910 billion	$3.2390 billion	View	Listen
11/6/2017	Q3 2017	$1.20	$1.10	$3.0927 billion	$2.9871 billion	View	N/A
8/9/2017	Q2 2017	$1.18	$1.10	$2.9975 billion	$2.9622 billion	View	Listen
5/10/2017	Q1 17	$0.92	$0.93	$2.8130 billion	$2.7195 billion	View	N/A
3/1/2017	Q4 2016	$1.42	$1.57	$3.1754 billion	$3.2678 billion	View	N/A
11/9/2016	Q3 2016	$1.50	$1.38	$3.12 billion	$3.06 billion	View	Listen
8/9/2016	Q216	$1.13	$1.16	$2.58 billion	$2.56 billion	View	N/A
5/3/2016	Q116	$0.74	$0.76	$2.23 billion	$2.19 billion	View	N/A
2/10/2016	Q415	$1.27	$1.22	$2.71 billion	$2.4907 billion	View	Listen
10/30/2015	Q315	$1.38	$1.43	$2.79 billion	$2.71 billion	View	Listen
8/6/2015	Q215	$0.89	$0.91	$2.39 billion	$2.37 million	View	N/A
5/5/2015	Q115	$0.70	$0.70	$2.2220 billion	$1.8717 billion	View	Listen
3/2/2015	Q414	$1.05	$1.05	$2.07 billion	$2.08 billion	View	Listen
10/30/2014	Q314	$1.14	$1.16	$2.06 billion	$2.08 billion	View	N/A
8/7/2014	Q214	$0.70	$0.69	$1.88 billion	$1.84 billion	View	N/A
5/1/2014	Q114	$0.63	$0.66	$1.80 billion	$1.72 billion	View	N/A
2/27/2014	Q413	$0.75	$0.78	$1.81 billion	$1.81 billion	View	N/A
10/31/2013	Q313	$0.79	$0.82	$1.84 billion	$1.77 billion	View	N/A
8/1/2013	Q2 2013	$0.67	$0.68	$1.73 billion	$1.70 billion	View	N/A
5/2/2013	Q1 2013	$0.62	$0.62	$1.6939 billion	$1.6315 billion	View	N/A
2/27/2013	Q4 2012	$0.64	$0.65	$1.73 billion	$1.72 billion	View	N/A
10/25/2012		$0.77	$0.83			View	N/A
7/26/2012		$0.55	$0.60			View	N/A
4/26/2012		$0.51	$0.52			View	N/A
2/21/2012		$0.50	$0.53			View	N/A
10/26/2011		$0.51	$0.55			View	N/A
7/27/2011		$0.45	$0.52			View	N/A
5/3/2011		$0.44	$0.44			View	N/A
2/24/2011		$0.45	$0.45			View	N/A
10/26/2010	Q3 2010	$0.42	$0.43			View	N/A
7/28/2010	Q2 2010	$0.38	$0.37			View	N/A
4/29/2010	Q1 2010	$0.34	$0.36			View	N/A
2/25/2010	Q4 2009	$0.30	$0.33			View	N/A
10/29/2009	Q3 2009	$0.27	$0.32			View	N/A
7/30/2009	Q2 2009	$0.29	$0.32			View	N/A
4/30/2009	Q1 2009	$0.27	$0.22			View	N/A
2/19/2009	Q4 2008	$0.14	$0.26			View	N/A
10/30/2008	Q3 2008	$0.12	$0.23			View	N/A
8/6/2008	Q2 2008	$0.10	$0.16			View	N/A
5/8/2008	Q1 2008	$0.08	$0.09			View	N/A
2/27/2008	Q4 2007	($0.06)	$0.11			View	N/A

(Earnings results data provided by Zacks Investment Research)

Mylan (NASDAQ:MYL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Mylan (NASDAQ MYL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 84.53%

Insider Trading History for Mylan (NASDAQ:MYL)

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2018	Paul Campbell	Insider	Sell	7,030	$44.01	$309,390.30	17,054
3/6/2018	Robert J. Coury	Director	Sell	50,000	$43.41	$2,170,500.00
3/2/2018	Anthony Mauro	Insider	Sell	12,257	$40.35	$494,569.95	147,435
3/2/2018	Rajiv Malik	President	Sell	50,000	$40.91	$2,045,500.00	503,751
3/2/2018	Robert J. Coury	Director	Sell	150,000	$40.10	$6,015,000.00
1/9/2018	Heather M. Bresch	CEO	Sell	75,000	$45.00	$3,375,000.00
6/9/2017	Anthony Mauro	Insider	Sell	10,000	$40.00	$400,000.00	140,653
6/9/2017	Rajiv Malik	President	Sell	25,000	$40.00	$1,000,000.00	799,855
3/23/2017	Laboratories Abbott	Major Shareholder	Sell	44,000,000	$41.60	$1,830,400,000.00
8/9/2016	Heather M Bresch	CEO	Sell	100,200	$50.00	$5,010,000.00	828,318
6/3/2016	Joseph C Md Maroon	Director	Buy	1,670	$44.95	$75,066.50	22,036
5/25/2016	Robert J Cindrich	Director	Buy	1,190	$42.47	$50,539.30	13,384
5/12/2016	Melina E Higgins	Director	Buy	19,900	$38.68	$769,732.00	1,872
5/6/2016	Melina E Higgins	Director	Buy	100	$38.69	$3,869.00	1,872
4/28/2016	Melina E Higgins	Director	Buy	35,000	$42.92	$1,502,200.00
4/5/2016	Robert J Coury	Chairman	Sell	217,755	$45.96	$10,008,019.80	1,334,306
3/31/2016	Joseph C Md Maroon	Director	Buy	4,337	$46.36	$201,063.32	16,124
3/17/2016	Mark W Parrish	Director	Buy	1,705	$44.00	$75,020.00	31,365
3/8/2016	Wendy Cameron	Director	Buy	2,190	$45.69	$100,061.10	66,677
3/3/2016	Robert J Cindrich	Director	Buy	2,187	$45.83	$100,230.21	10,322
12/17/2015	John D. Sheehan	CFO	Sell	34,579	$55.03	$1,902,882.37	171,251
6/15/2015	Melina E Higgins	Director	Sell	8,351	$73.08	$610,291.08
2/3/2015	Anthony Mauro	Insider	Sell	13,255	$53.15	$704,503.25
2/3/2015	Heather M Bresch	CEO	Sell	411,996	$53.15	$21,897,587.40
2/3/2015	Rajiv Malik	President	Sell	285,394	$53.15	$15,168,691.10
2/3/2015	Robert J Coury	Chairman	Sell	947,119	$52.55	$49,771,103.45
2/3/2015	Rodney L Piatt	Director	Sell	46,000	$53.15	$2,444,900.00
11/26/2014	John D Sheehan	CFO	Sell	19,475	$57.50	$1,119,812.50
11/25/2014	Heather M Bresch	CEO	Sell	100,000	$55.80	$5,580,000.00
11/25/2014	Rajiv Malik	President	Sell	120,000	$55.78	$6,693,600.00
11/25/2014	Robert J Coury	Chairman	Sell	165,700	$55.78	$9,242,746.00
11/24/2014	Heather M Bresch	CEO	Sell	80,222	$55.86	$4,481,200.92
11/24/2014	Rajiv Malik	President	Sell	84,300	$55.86	$4,708,998.00
11/24/2014	Robert J Coury	Chairman	Sell	105,800	$55.88	$5,912,104.00
11/7/2014	Melina E Higgins	Director	Buy	14,000	$52.45	$734,300.00
9/18/2014	Neil F Dimick	Director	Sell	5,432	$48.26	$262,148.32
6/19/2014	Neil F Dimick	Director	Sell	5,432	$50.81	$275,999.92
4/22/2014	Rajiv Malik	President	Sell	80,000	$50.00	$4,000,000.00	289,117
4/14/2014	Heather Bresch	CEO	Sell	75,000	$46.07	$3,455,250.00	293,418
3/20/2014	Neil Dimick	Director	Sell	5,813	$53.08	$308,554.04	32,136
3/14/2014	C Todd	Director	Sell	10,000	$53.00	$530,000.00	23,389
3/6/2014	Harry Korman	COO	Sell	31,970	$54.54	$1,743,643.80	133,373
3/3/2014	Anthony Mauro	Insider	Sell	20,000	$54.81	$1,096,200.00	25,473
3/3/2014	Daniel Rizzo, Jr.	CAO	Sell	8,003	$55.50	$444,166.50	82,296
3/3/2014	Douglas Leech	Director	Sell	10,000	$55.40	$554,000.00	36,271
1/2/2014	Neil Dimick	Director	Sell	5,813	$43.15	$250,830.95	32,136
12/19/2013	Rodney Piatt	Director	Sell	10,000	$41.84	$418,400.00	62,436
12/12/2013	Daniel Rizzo, Jr.	CAO	Sell	70,683	$42.04	$2,971,513.32	68,971
12/12/2013	Melina Higgins	Director	Buy	5,000	$42.03	$210,150.00
9/6/2013	Heather M Bresch	CEO	Sell	160,000	$35.35	$5,656,000.00
6/3/2013	Neil F Dimick	Director	Sell	19,994	$30.51	$610,016.94
11/27/2012	Daniel C Rizzo Jr	CAO	Sell	161,124	$27.28	$4,395,462.72
11/2/2012	Douglas J Leech	Director	Sell	44,280	$25.94	$1,148,623.20
11/1/2012	Anthony Mauro	Insider	Sell	12,301	$25.79	$317,242.79
10/5/2012	Anthony Mauro	Insider	Sell	12,296	$24.84	$305,432.64

(Data available from 1/1/2013 forward)

Mylan (NASDAQ MYL) News Headlines

Source:

Date	Headline
	Mylan cuts 15 percent of workforce at West Virginia plant www.reuters.com - April 20 at 5:19 PM
	Mylan NV Could Be Closer to a Breakout Than Most Traders Realize investorplace.com - April 19 at 2:51 PM
	Mylan (MYL) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 19 at 11:51 AM
	[$$] Drugmakers take unorthodox route to boosting biosimilars finance.yahoo.com - April 18 at 5:11 PM
	Canada seeks US help to solve EpiPen shortage www.reuters.com - April 18 at 8:55 AM
	Canada seeks U.S. help to solve EpiPen shortage finance.yahoo.com - April 18 at 8:55 AM
	Q4 2018 EPS Estimates for Mylan (MYL) Raised by Analyst www.americanbankingnews.com - April 18 at 8:39 AM
	UPDATE 1-Canada says working with US FDA to address EpiPen shortage www.reuters.com - April 17 at 5:22 PM
	Canada says working with U.S. FDA to address EpiPen shortage finance.yahoo.com - April 17 at 5:22 PM
	Q4 2018 EPS Estimates for Mylan Lowered by Analyst (MYL) www.americanbankingnews.com - April 16 at 2:33 AM
	$2.79 Billion in Sales Expected for Mylan (MYL) This Quarter www.americanbankingnews.com - April 15 at 6:59 AM
	EpiPen shortages seen in Canada, UK but US supply intact www.reuters.com - April 14 at 8:40 AM
	Mylan (MYL) Given "Hold" Rating at Cowen www.americanbankingnews.com - April 13 at 6:01 PM
	Mylan seeks deal for Merck's consumer products unit www.cnbc.com - April 13 at 2:52 PM
	Mylan aiming for Merck KGaA's consumer unit seekingalpha.com - April 13 at 12:33 PM
	Mylan seeks deal for German Merck's consumer products unit: sources www.reuters.com - April 13 at 8:45 AM
	Mylan seeks deal for German Merck's consumer products unit - sources finance.yahoo.com - April 13 at 8:45 AM
	Wired News - Mylan to Collaborate with Fujifilm Kyowa Kirin Biologics for Commercializing Biosimilar to Humira(R) (adalimumab) finance.yahoo.com - April 13 at 8:45 AM
	Q1 2018 Earnings Estimate for Mylan (MYL) Issued By Leerink Swann www.americanbankingnews.com - April 13 at 8:33 AM
	Mylan (MYL) Sees Large Drop in Short Interest www.americanbankingnews.com - April 13 at 3:23 AM
	$1.04 Earnings Per Share Expected for Mylan (MYL) This Quarter www.americanbankingnews.com - April 13 at 1:23 AM
	Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar www.zacks.com - April 12 at 5:19 PM
	Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms finance.yahoo.com - April 12 at 5:19 PM
	Analyst Urges Investors To Buy This Drugmaker's Dip — And They Do finance.yahoo.com - April 12 at 5:19 PM
	Mylan's Stock Gets Bump After Investor Day finance.yahoo.com - April 12 at 5:19 PM
	Mylan (MYL) Upgraded by Leerink Swann to Outperform www.americanbankingnews.com - April 12 at 10:51 AM
	JPMorgan Chase Analysts Give Mylan (MYL) a $53.00 Price Target www.americanbankingnews.com - April 12 at 10:23 AM
	Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug finance.yahoo.com - April 12 at 9:09 AM
	Mylan Spotlights Diversification at Investor Day finance.yahoo.com - April 12 at 9:09 AM
	Wells Fargo Analysts Give Mylan (MYL) a $30.00 Price Target www.americanbankingnews.com - April 11 at 7:53 PM
	Mylan (MYL) Given a $41.00 Price Target at Cantor Fitzgerald www.americanbankingnews.com - April 11 at 6:14 PM
	Investor Day Highlights Durability of Mylan's Global Platform finance.yahoo.com - April 11 at 5:13 PM
	Mylan to Leverage its World-Class Scientific Platform to Develop a Novel Delivery for Meloxicam, a Non-Opioid Pain Medication finance.yahoo.com - April 11 at 5:13 PM
	Mylan (MYL) Issues FY18 Earnings Guidance www.americanbankingnews.com - April 11 at 2:19 PM
	Mylan (MYL) Rating Reiterated by Cowen www.americanbankingnews.com - April 11 at 1:20 PM
	Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day finance.yahoo.com - April 11 at 8:52 AM
	Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab) finance.yahoo.com - April 11 at 8:52 AM
	Mylan (MYL) Rating Reiterated by Royal Bank of Canada www.americanbankingnews.com - April 10 at 8:23 PM
	Mylan acquires marketing rights to multiple sclerosis drug finance.yahoo.com - April 10 at 5:16 PM
	Mylan to acquire global marketing rights to MS treatment from Israel's Mapi Pharma finance.yahoo.com - April 10 at 8:34 AM
	Mylan to buy marketing rights to MS treatment from Israel's Mapi Pharma finance.yahoo.com - April 10 at 8:34 AM
	Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma finance.yahoo.com - April 10 at 8:34 AM
	Morgan Stanley Reiterates $50.00 Price Target for Mylan (MYL) www.americanbankingnews.com - April 9 at 6:25 PM
	RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON FROM MYLAN www.lse.co.uk - April 9 at 5:17 PM
	RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLAN feeds.benzinga.com - April 9 at 4:09 AM
	Mylan (MYL) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 7 at 4:58 PM
	Mylan Announces Pricing Of Private Offering Of $1.5 Bln Of Senior Note www.nasdaq.com - April 6 at 8:24 AM
	BRIEF-Mylan Extends Debt Maturities With $1.5 Billion Bond Offering www.reuters.com - April 6 at 8:24 AM
	Mylan Strengthens Its Capital Structure by Extending Its Debt Maturities with a Successful $1.5 Billion Bond Offering finance.yahoo.com - April 6 at 8:23 AM
	Mylan N.V. -- Moody's assigns Baa3 to Mylan's offering finance.yahoo.com - April 4 at 4:37 PM

Mylan (NASDAQ:MYL) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Mylan (NASDAQ:MYL) Income Statement, Balance Sheet and Cash Flow Statement

Mylan (NASDAQ MYL) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff